ABUS
NASDAQ
$4.41
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $5.19 (+17.69%)
Market Cap
$898M
Revenue 5Y CAGR
+90.98%
Profit Margin
94.7%
P/E Ratio
5.60
Price Chart
Valuation
Market Cap$898M
P/E5.60
Forward P/E10.25
P/S4.76
P/B3.54
Profitability
Total Revenue (TTM)$191M
Gross Profit (TTM)$171M
EBITDA$156M
Profit Margin94.7%
Operating Margin94.3%
EPS$0.81
Financial Health
Free Cash Flow Yield-3.83%
Growth & Risk
Revenue 5Y CAGR+90.98%
FCF 5Y CAGR-8.71%
Beta (5Y)0.88
Sharpe Ratio0.88